Atossa Therapeutics (NASDAQ:ATOS) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Atossa Therapeutics (NASDAQ:ATOS) released its earnings results on Monday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01, Yahoo Finance reports.

Atossa Therapeutics Stock Up 0.8 %

NASDAQ:ATOS opened at $1.31 on Wednesday. Atossa Therapeutics has a 52 week low of $0.62 and a 52 week high of $2.31. The stock has a market capitalization of $164.74 million, a PE ratio of -5.42 and a beta of 1.21. The stock’s 50-day moving average price is $1.24 and its 200-day moving average price is $1.33.

Analyst Upgrades and Downgrades

ATOS has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Atossa Therapeutics in a research report on Monday. Ascendiant Capital Markets increased their price target on Atossa Therapeutics from $6.00 to $6.25 and gave the stock a “buy” rating in a research report on Thursday, June 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Atossa Therapeutics in a research report on Thursday, June 20th. Finally, StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.